December 4th 2024
Your daily dose of the clinical news you may have missed.
December 2nd 2024
November 27th 2024
A woman in her early 50s presents with 6 hours of right sided pleuritic chest pain. What do the history and ECG suggest? What's yoru Dx?
November 26th 2024
The patient shows no signs of trauma but is a poor historian so no further details are available. Do her vitals or ECG provide any clues to a Dx?
November 25th 2024
Daily Dose: Healthy Lifestyle & Risk of CVD Among Postmenopausal Women With Normal BMI
Your daily dose of clinical news you may have missed.
Home Blood Pressure Monitoring among Older US Adults
Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.
Daily Dose: Cardiovascular Safety of Testosterone-Replacement Therapy in Men with Hypogonadism
Healthy Lifestyle Linked to Primary CVD Prevention in Postmenopausal Women with Normal BMI
Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.
FDA Approves Low-Dose Colchicine as First Anti-inflammatory Therapy to Reduce Cardiovascular Events
Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.
Testosterone Replacement Does Not Increase Risk for CV Events in Men with Hypogonadism, New Study Finds
ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.
Daily Dose: Bempedoic Acid Found Comparable to Statins for Lowering LDL-C
Friday's 5 Quotes for Primary Care 6-19-2023
Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.
Bempedoic Acid Found Comparable to Statins for Lowering LDL-C, Reducing Major CV Event Risk
ENDO 2023: Treatment with bempedoic acid was found comparable to statin therapy in an analysis of the CLEAR Outcomes trial based on CTT Collaboration methodology.
Daily Dose: Postmenopausal Women Using Oral Estrogen Hormone Therapy More Likely to Develop HTN
Daily Dose: Finerenone Reduces CKD-associated CV Risk in Patients with T2D
Risk of Hypertension in Postmenopausal Women Higher with Oral Estrogen-only Hormone Therapy
Oral estrogen hormone therapy was more likely to result in incident hypertension than transdermal or vaginal formulations in this large prospective population-based study.
Finerenone Reduces CKD-associated Composite Cardiovascular Risk in a New Subanalysis of FIDELITY Trial
Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.
Elevated Lp(a) Levels Found Independent Predictors of Recurrent CHD in Australian Cohort
Increased levels of lipoprotein(a) significantly and independently predicted recurrent CHD events in adults aged 60 years and older, report study authors.
Friday's 5 Quotes for Primary Care 6-9-2023
FDA fast tracks triple-threat antithrombotic, dangers of faux semaglutide online, a guide to neurologic sequelae of COVID-19, plus 2 more reviews of note.
Milvexian, FXIa Inhibitor, Wins US FDA Fast Track Designation for 3 Indications in Phase 3 Trial Program
Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
Daily Dose: Adherence to GLP1RA, SGLT2i Therapies & Prescription Copayment Level
Lower Adherence with GLP1RA, SGLT2i Therapies Linked to Higher Prescription Copayments
In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.
The Long COVID Neuro Differential Dx: Sometimes Tricky, Always Nuanced
Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.
Friday's 5 Quotes for Primary Care 6-2-2023
The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.
Diabetes Associated with Higher Risk of Death in Persons Hospitalized with Acute Myocardial Infarction
After an acute myocardial infarction, adults with diabetes were over 50% more likely to die after 1 year than those without diabetes, a new study shows.
Daily Dose: Subclinical CVD Affects 1 in 3 US Adults with Diabetes
Long COVID was Apparent by Summer 2020 and in a Wide Range of Patients
Symptoms of long COVID were apparent by the summer of 2020, said physiatrist Dr Leslie Rydberg, coauthor of new consensus guidelines on management of neurologic sequelae.
One in 3 US Adults with T2D Shows Evidence of Subclinical CVD Based on Cardiac Biomarkers
As indicated by levels of 2 common biomarkers of cardiac injury, 33.4% of US adults with T2D showed evidence of undetected CVD vs only 16.1% of those without T2D.
FDA Approves SGLT-2/1 Inhibitor Sotagliflozin, Grants Broad Heart Failure Indication
The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.
Comorbidities Associated with COPD Affect Outcomes, Require Attention
At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.
Asundexian Granted FDA Fast Track Designation for Stroke Prevention in Patients with AF
Bayer's investigational FXIa inhibitor is currently being studied in a large-scale phase 3 development program expected to enroll more than 27 000 participants.
Daily Dose: Global Deaths from Ischemic Stroke May Reach 5 Million by 2030
Statin Therapy May be Protective Against Stroke in People with Atrial Fibrillation: New Study
Statin therapy initiated within 1 year of diagnosis of atrial fibrillation reduced the risk of ischemic stroke or systemic embolism by nearly 20%.
Global Deaths from Ischemic Stroke May Reach 5 Million by 2030, According to New Study
Findings also showed that between 1990 and 2019, the global number of ischemic stroke deaths rose from 2 million to 3 million.